Antihistamines are frequently used to treat allergy symptoms. Misuse of antihistamines has been documented primarily in adolescents and young adults; however, antihistamine involvement in overdose deaths has not been widely studied. Among the various antihistamine subtypes, the first-generation H1 subtype can cause anticholinergic effects, including strong sedation that might be exacerbated when co-used with other sedative drugs (e.g., opioids).* Diphenhydramine, a common over-the-counter first-generation H1 antihistamine, has been combined with opioids as an adulterant† in illicit drug supply and can be used to reduce opioid-related side effects (e.g., itchy skin because of histamine release from opioid use).
To describe unintentional and undetermined intent overdose deaths with antihistamine positivity, involvement, or both, CDC analyzed available 2019–2020 data from the State Unintentional Drug Overdose Reporting System (SUDORS) in 43 states and the District of Columbia.§,¶ A death was defined as antihistamine-positive if any antihistamine was detected on postmortem toxicology or was listed as a cause of death on the death certificate.** A death was defined as antihistamine-involved if the drug class was listed as a cause of death on the death certificate (i.e., antihistamine-involved is a subset of antihistamine-positive). Descriptive data for deaths are presented by sex, age, race and ethnicity, U.S. Census Bureau region,†† and other drugs involved. Analyses were restricted to decedents for whom postmortem toxicology results were available.§§
Among 92,033 overdose deaths during 2019–2020, 13,574 (14.7%) were antihistamine-positive and 3,345 (3.6%) were antihistamine-involved; fewer than 0.1% (90) involved antihistamines alone (Table). Nearly all antihistamine-positive and -involved deaths (13,475, 99.6%; 3,339, 99.8%, respectively) included first-generation H1 antihistamines, primarily diphenhydramine (9,645, 71.1%; 2,226, 66.5%, respectively). The proportions of antihistamine- and diphenhydramine-involved overdose deaths were highest for females (52.0%; 52.8%), persons aged 35–44 years (26.1%; 26.5%), and White, non-Hispanic persons (78.1%; 78.7%); demographic patterns of antihistamine- and diphenhydramine-positive deaths were similar, except that deaths were more frequent among males (57.8%; 59.6%) and in the Midwest region (43.6%; 51.0%). Most antihistamine- and diphenhydramine-involved overdose deaths co-involved opioids (82.8% and 82.7%, respectively), primarily illicitly manufactured fentanyls (IMFs)¶¶.
Nearly 15% of overdose deaths during 2019–2020 were antihistamine-positive, and 4% were antihistamine-involved; only 90 deaths involved antihistamines as the sole drug. Most antihistamine-positive and antihistamine-involved deaths included diphenhydramine, which is easily accessible over the counter as an allergy medication and sleep aid. Antihistamine-involved deaths commonly co-involved opioids; this might be partly attributable to adulteration of the illicit opioid supply with antihistamines, in particular diphenhydramine, which can be dangerous because of potentially combined sedative effects. Naloxone administration is important for any overdose with suspected opioid involvement. Because antihistamines do not respond to naloxone, co-involved opioid and antihistamine overdoses might require naloxone administration plus other immediate medical response measures to prevent death.
The findings in this report are subject to at least two limitations. First, results included 44 jurisdictions and might not be nationally representative. Second, drug testing methods are not standardized across jurisdictions, which might limit interpretation of results. Antihistamine-positivity could reflect use to treat allergy or other symptoms rather than misuse. It is also possible that some persons did not knowingly consume antihistamines and were exposed to these drugs through adulteration of the illicit drug supply with antihistamines. Despite these limitations, these data highlight the importance of continued surveillance to understand the drugs and drug combinations contributing to overdose deaths and to guide awareness efforts about the potential dangers of the unpredictable illicit drug supply and the intentional or unintentional co-use of substances, including antihistamines and opioids.
Jurisdictions participating in CDC's Overdose Data to Action (OD2A) program and providing data to the State Unintentional Drug Overdose Reporting System, including jurisdictional health departments, vital registrar offices, and coroner and medical examiner offices; Nicole L. Davis, Kyle Suen, Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC; CDC OD2A team, Division of Overdose Prevention, National Center for Injury Prevention and Control, CDC.
Morbidity and Mortality Weekly Report. 2022;71(41):1308-1310. © 2022 Centers for Disease Control and Prevention (CDC)